

# Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Information for the public

Published: 3 April 2024

[www.nice.org.uk](http://www.nice.org.uk)

Dostarlimab (Jemperli) is available with [managed access](#) as a possible treatment for primary advanced or recurrent endometrial cancer in adults if:

- the cancer has high microsatellite instability or mismatch repair deficiency and
- they are candidates for systemic treatment (treatments that work throughout the whole body, such as injections, infusions or medicines taken by mouth).

More evidence on dostarlimab is being collected. After this, NICE will decide whether or not to recommend dostarlimab for routine use in the NHS and update the guidance. It will be available with managed access until then.

If you are not eligible for dostarlimab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on womb cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Peaches Womb Cancer Trust](#)
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5858-0